PMID- 14759320
OWN - NLM
STAT- MEDLINE
DCOM- 20040422
LR  - 20160607
IS  - 0578-1310 (Print)
IS  - 0578-1310 (Linking)
VI  - 41
IP  - 2
DP  - 2003 Feb
TI  - [Results of Wilms' tumor trial (WT-99) in Shanghai children's medical center].
PG  - 131-4
AB  - OBJECTIVE: Wilms' Tumor Trial (WT-99) of Shanghai Children's Medical Center was 
      designed and conducted by applying therapeutic regimens stratified by stage and 
      histology in accordance with National Wilms' Tumor Study (NWTS) criteria of 
      U.S.A. The main aim of WT-99 was to reduce treatment of low-stage, 
      favorable-histology (FH) tumors without impairing survival and to improve 
      prognosis of stage III and IV (FH) and unfavorable-histology (UFH) tremors with 
      more intensive chemotherapy. METHODS: Diagnosis and treatment was decided by the 
      multi-disciplinary team including oncologists, surgeons, pathologists, 
      radiologists and diagnostic radiologists. Twenty consecutively diagnosed patients 
      were recruited between October 1998 and October 2002. The regimen for patients at 
      favorable-histology (FH) stage I and II and anaplastic stage I was vincristine 
      (Vcr) and dactinomycin (Act-D) only, while for those at focal anaplastic stage II 
      to IV and FH stage III and IV the regimen was Vcr, Act-D and adriamycin (Adr). 
      Patients at diffuse anaplastic stage II to IV and clear cell stage I to IV 
      received four-drug regimen including Vcr, etoposide (VP16), Adr and cytoxan 
      (CTX). For those at rhabdoid stage I to IV the regimen was carboplatin, VP-16 and 
      CTX. Un-resectable patients received 2 courses of Ifosfamide, Vcr and VP-16 as 
      pre-surgery therapy. No radiation therapy was used for patients at stage I and FH 
      stage II. RESULTS: Twenty patients, from 7 months to 12 years old, were enrolled. 
      Pathologic analysis showed fourteen cases were at their FH, three at 
      unfavorable-histology (UFH), two at clear cell and one at rhabdoid stage. Five 
      patients were at stage I, five at stage II, six at stage III, three at stage IV 
      and one at stage V. Eighteen reached complete response (90%), and two failed. One 
      relapsed after 24 months of CCR and reached the second CR after intensive 
      chemotherapy. No therapy-related death happened. Survival rate (SR) was 90% 
      (18/20) and event-free survival (EFS) was 85% (17/20) at 11-45 months, average 27 
      months. CONCLUSION: Multi-disciplinary team work model and protocol WT-99 are 
      safe and effective for Wilms' tumor.
FAU - Tang, Jing-yan
AU  - Tang JY
AD  - Department of Hematology/Oncology, XinHua Hospital/Shanghai Children's Medical 
      Center, Shanghai Second Medical University, Shanghai 200127, China.
FAU - Pan, Ci
AU  - Pan C
FAU - Xu, Min
AU  - Xu M
FAU - Xue, Hui-liang
AU  - Xue HL
FAU - Chen, Jing
AU  - Chen J
FAU - Zhao, Hui-lun
AU  - Zhao HL
FAU - Gu, Long-lun
AU  - Gu LL
FAU - Wang, Yao-ping
AU  - Wang YP
LA  - chi
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Er Ke Za Zhi
JT  - Zhonghua er ke za zhi = Chinese journal of pediatrics
JID - 0417427
SB  - IM
MH  - Academic Medical Centers
MH  - Bone Transplantation
MH  - Child
MH  - Child, Preschool
MH  - China
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - Infant
MH  - Kidney Neoplasms/classification/*therapy
MH  - Male
MH  - Neoplasm Staging
MH  - Transplantation, Autologous
MH  - Treatment Outcome
MH  - Wilms Tumor/classification/*therapy
EDAT- 2004/02/05 05:00
MHDA- 2004/04/23 05:00
CRDT- 2004/02/05 05:00
PHST- 2004/02/05 05:00 [pubmed]
PHST- 2004/04/23 05:00 [medline]
PHST- 2004/02/05 05:00 [entrez]
PST - ppublish
SO  - Zhonghua Er Ke Za Zhi. 2003 Feb;41(2):131-4.